Marc Lenoir

Marc Lenoir is an Associate Director in Biologics Engineering at AstraZeneca, focusing on protein engineering and new modalities in oncology. They previously served as a Group Leader in Discovery Research at Adaptimmune, where they led teams in developing T-cell products and enhancing pipeline capabilities. Marc holds a PhD from the University of Edinburgh, where their research centered on RGD-based contrast agents targeting neoangiogenesis markers. They have also worked as a Postdoctoral Research Fellow at the University of Birmingham, specializing in membrane-associated proteins and fragment-based drug discovery.